NPCE · NeuroPace Inc
Market Cap
$481.91M
Shares
34.32M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.04
Open$14.04
Day$13.82–14.13
52W close$9.40–19.29
Avg vol 30d181K
Short int911K · 2.7% float · 6.3d
Short vol66%
Last earningsAug 11, 2026
DataApr 2021–Sep 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 7, 2026
Est · unconfirmed
· in 8 wks
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$102.86M
Trailing 12 months
Net income (TTM)
−$19.11M
Trailing 12 months
Revenue growth YoY
+17.1%
Year over year
Operating margin
-13.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.8%
Year over year · more shares
Price change (1Y)
+40.3%
Trailing year
Short interest
2.7%
Latest settlement · 6.3 days to cover
AI Brief
Q2 FY26 earnings call · Aug 11, 2026
Q2 FY26
TL;DR. NeuroPace reported Q2 2026 RNS revenue of $22.5 million (21.3% growth) and raised full-year 2026 revenue guidance to $99.5M-$101.5M and adjusted gross margin to 82-83%, while the IGE PMA supplement received a not-approvable letter from the FDA prompting an SIR process.
Bullish
- + Q2 RNS system revenue grew 21.3% to $22.5 million, with first-half RNS growth of 20.4% in line with the long-term framework
- + Raised full-year 2026 total revenue guidance to $99.5M-$101.5M from $99M-$101M
- + Q2 adjusted EBITDA loss narrowed to $2.8M from $4.9M and GAAP net loss improved to $6.2M from $10.0M
Bearish
- − FDA informed NeuroPace the IGE PMA supplement was not approvable in its current form, requesting additional information
- − Management acknowledged IGE approval timing has slipped versus prior expectation of mid-2026
- − Non-GAAP gross margin declined slightly to 83.4% from 84.0% on higher material costs
- − Service revenue declined to $302K from $937K, a headwind of more than 300 basis points to total revenue growth
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
−6%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
47%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−3%
trailing
6-month return
+8%
trailing
YTD return
−9%
this year
Relative strength
−10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $15 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.66% of float · ▲ +7.8% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+25%
Y/Y
Gross margin
77%
expanding
EPS growth
+29%
Y/Y
Free cash flow
$-11.3M
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 11, 2026
full year 2026
Total revenue
Initiated
$99.5M – $101.5M
prior FY $99.99M
midpoint +0.5% Y/Y
RNS revenue
Initiated
$98.5M – $100.5M
Adjusted gross margin
Non-GAAP
Initiated
82% – 83%
Adjusted operating expenses
Non-GAAP
Initiated
$90M – $92M
Adjusted sales and marketing expense
Non-GAAP
Initiated
$46M – $48M
full year
Adjusted research and development expense
Non-GAAP
$27M
Prior guidance
period ended
· from the 8-K filed Aug 13, 2024
Gross margin
· full year 2024
72% – 74%
Total operating expenses
· full year 2024
$80M – $84M
Guided vs delivered
· last 3 settled
Annual revenue
2022
guided $45M – $48M
$45.52M
In line
Total revenue
first quarter 2022
guided $10M – $11M
$11.37M
Beat +8.3%
Full-year total revenue
full-year 2021
guided $47M
$45.18M
Miss −3.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
47%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $15 › 200d $15 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.66% of float · ▲ +7.8% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9
Now $14 · 47%
Range high $19
vs 200-day avg -9%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NPCE
this stock
NeuroPace Inc
|
$481.91M | -9.1% | +25.1% | — | 2.7% |
|
ABT
Abbott Laboratories
|
$177.58B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$116.35B | -5.3% | +8.4% | 22.4 | 0.9% |
|
SYK
Stryker Corp
|
$105.70B | -21.6% | +11.2% | 28.6 | 2.0% |
|
BSX
Boston Scientific Corp
|
$64.91B | -54.9% | +12.5% | 18.1 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NPCE | -4.8% | -3.2% | +8.0% | -4.2% | -9.1% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -3.7% | -1.5% | -9.8% | -3.8% | -21.2% |